Zylox PanFlex Percutaneous Transluminal Angioplasty Scoring Catheter
Zylox Medtech Co., Ltd. · Decision date Oct 22, 2026
What did the FDA decide?
The FDA recorded a substantial equivalence determination, decision code SESE, on October 22, 2026 for the Zylox PanFlex Percutaneous Transluminal Angioplasty Scoring Catheter, submitted by Zylox Medtech Co., Ltd. under section 510(k) premarket notification K260686. The device is listed under product code PNO with a Cardiovascular specialty. The decision letter addresses Siran Wu as regulatory affairs specialist and states that the device is substantially equivalent to legally marketed predicate devices for the indications for use given in the enclosure.
SESE denotes 510(k) clearance rather than premarket approval, so the record covers a finding of substantial equivalence, not a new PMA. The source data do not include the indications for use, the predicate devices named, or any component-level description of the scoring catheter, so the specific design and labeled use remain unknown from this record. No clinical or efficacy conclusions are drawn here.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 22, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260686
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Zylox Medtech Co., Ltd.
- Product code
- PNO
- Decision code
- SESE
- Decision date
- Oct 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, Percutaneous, Cutting/Scoring.
- Applicant
- Zylox Medtech Co., Ltd.
- Product code
- PNO
- FDA device class
- 2
FDA decision timeline
K260686 received
Application receipt date recorded by FDA.
K260686 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code PNO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| OrbusNeich Medical (Shenzhen) Co., Ltd. | 510(k) clearance | Sep 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Zylox Medtech Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Hangzhou
Sources and methodology
- Original FDA record: K260686
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records